SenzaGen’s 2022 Year-End Report: Breakthrough for SenzaGen in both sales and technology

Message from the CEO

“We closed our breakthrough year, 2022, on a very strong note with a 110% increase in sales for the second half year to SEK 21.8 million. Organic sales accounted for SEK 12.1 million, representing 70% organic growth. Late in the year, we saw strong demand for GARD® tests, which was largely driven by the OECD approval received earlier in the year. For the full year, total sales increased by as much as 171% to SEK 41.8 million. With our OECD-approved test, new innovative tests and a broader offering in a market that is continuing to grow from technological, regulatory and ethical drivers, I can see us in a very favorable position for continued high growth.”

Peter Nählstedt, President and CEO

Full year 1 January–31 December

  • Net sales totaled SEK 41.8 (15.4) million.
  • EBITDA amounted to SEK -15.7 (-27.3) million.
  • Earnings per share were SEK -1.03 (-1.35).
  • Cash and cash equivalents at 31 December amounted to SEK 40.0 (69.2) million.
  • The board proposes that no dividend be paid to the Company’s shareholders.

Second half year 1 July–31 December

  • Net sales totaled SEK 21.8 (10.4) million.
  • EBITDA amounted to SEK -6,6 (-15.5) million.
  • Earnings per share were SEK -0.47 (-0.78).

Significant events during the second half year

  • SenzaGen completed its largest test order to date for GARD®skin from a new customer, a world leader in chemicals, for a cumulative value of approximately SEK 1 million.
  • SenzaGen acquired ToxHub, an Italian company offering toxicology advisory services with specific expertise in medical devices and pharmacology.

Livestream presentation
SenzaGen is pleased to invite press and investors to a livestream presentation at 14:00 on February 16. The presentation will be given by SenzaGen’s President and CEO Peter Nählstedt, followed by a Q&A session moderated by Redeye's analyst Gustaf Meyer. The presentation will be held in English.

Time: Thursday February 16, 14:00–15:00 CET.
Link to the livestream:

The presentation can be watched afterwards at SenzaGen’s website: